Current approved therapeutic strategies for IPF and LC treatment

Inhibition of LPA-LPAR1 and VEGF-VEGFR2 signaling in IPF

PDF) Molecular Mechanisms and Cellular Contribution from Lung

PDF) Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

Transforming growth factor (TGF)-β1-induced miR-133a inhibits myofibroblast differentiation and pulmonary fibrosis

Targeting metabolic dysregulation for fibrosis therapy

Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry

Luca TABBÍ, Medical Doctor, Doctor of Medicine

JCM, Free Full-Text

Up-regulated SPP1 increases the risk from IPF to lung cancer via activating the pro-tumor macrophages - Computational and Structural Biotechnology Journal

Traditional Chinese medicine inspired dual-drugs loaded inhalable nano-therapeutics alleviated idiopathic pulmonary fibrosis by targeting early inflammation and late fibrosis, Journal of Nanobiotechnology

Beatrice ARAMINI, MD PhD

Valentina MASCIALE, PostDoc Position

A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials, BMC Pulmonary Medicine

Idiopathic pulmonary fibrosis-specific Bayesian network integrating extracellular vesicle proteome and clinical information